Umbilical cord blood transplantation: the first 25 years and beyond.
Level 5 - mechanism / opinion, no new human data
Narrative and historical review without systematic literature search or primary data synthesis.
PubMed 23673863 · doi:10.1182/blood-2013-02-453175
What was done
The authors reviewed the 25-year evolution, clinical applications, and technological advancements of umbilical cord blood transplantation as an alternative hematopoietic stem cell source for hematologic and metabolic conditions.
What was found
The abstract reports no quantitative figures or statistical comparisons. It qualitatively notes high success rates for related and unrelated transplants in pediatric patients, improved outcomes in adults mediated by double cord blood units, better human leukocyte antigen matching, and adequate cell dosing, alongside faster engraftment times in cord blood expansion trials.
Why it matters
It summarizes the clinical adaptations that allowed cord blood grafting to overcome cell dose limitations and expand from a pediatric modality to an adult transplantation strategy.
Limits
The abstract contains no empirical data, sample sizes, or systematic review methodology. Comparative efficacy versus alternative stem cell sources is reported as under ongoing evaluation rather than conclusively established.
Cited by
- supports Hundreds of children have been successfully cured of blood disorders using cord blood stem cell transplants.